GLP-1 coverage, state by state
We publish a state guide when there are documents worth reading behind it. Right now that's 9 of the 51 states and the District of Columbia — not because the other 42 don't matter, but because we haven't read enough on them to write a page you could act on.
9 state guides published. Every source on every one of them was read first-hand and carries the date printed on the document.What these pages are, and what they are not
They're about what your state decided — whether its Medicaid program or its employee health plan pays for a GLP-1, when that changed, and what it left in place. Each one quotes the document it rests on and links to it.
They are not lists of which telehealth companies operate in your state. Of the 28 companies we grade, 4 publishes the states it's licensed in. We checked the other 23 and none of them says. A page here that ranked companies by state would be inventing the one fact you came for, so we don't.
The guides
| State | What it covers |
|---|---|
| Pennsylvania | Pennsylvania Medical Assistance stopped paying for GLP-1s for weight loss on January 1, 2026, kept them for every other approved use, and dropped Saxenda for all of them. 7 sourced facts · read September 2026 |
| California | Medi-Cal Rx removed Wegovy, Zepbound and Saxenda from its drug list on January 1, 2026, and pharmacy claims for them now reject outright — with two carve-outs worth knowing. 6 sourced facts · read September 2026 |
| New Hampshire | New Hampshire Medicaid dropped GLP-1s prescribed solely for weight loss on January 1, 2026 — a change documented by its managed-care plans rather than on a state website we could verify. 5 sourced facts · read September 2026 |
| North Carolina | North Carolina is the one state that ended Medicaid coverage of GLP-1s for obesity and then brought it back ten weeks later — and the version that returned has a step-therapy rule the old one didn't. 6 sourced facts · read September 2026 |
| South Carolina | South Carolina Medicaid's GLP-1 weight-management benefit lasted about fourteen months and ended on January 1, 2026 — recorded in a provider-manual change log rather than announced in a bulletin. 5 sourced facts · read September 2026 |
| Michigan | Michigan didn't cut GLP-1s for obesity — it rewrote the criteria so that coverage now turns on being classified as morbidly obese, failing other drugs first, and heading off bariatric surgery. 5 sourced facts · read September 2026 |
| Delaware | Delaware's benefits committee kept GLP-1 weight-loss coverage for state employees and attached a $200 copay per 30-day supply, after a cheaper $132 version failed on a recorded roll call. 4 sourced facts · read September 2026 |
| Colorado | Colorado moved the other way from most states on this site: from May 1, 2026 its employee health plans cover GLP-1s for weight loss — but on the larger plan it's Zepbound or nothing. 4 sourced facts · read September 2026 |
| Ohio | Ohio's Board of Pharmacy published dated end-points for compounding semaglutide and tirzepatide, banned the salt forms outright, and said retatrutide and cagrilintide cannot be compounded at all. 4 sourced facts · read September 2026 |
Why there aren't fifty of these
A state page is worth writing when we've read something real about that state. Fifty pages built from one template with a name swapped in would take a week and tell you nothing, and search engines are markedly better at spotting that than they were. We'd rather publish 9 pages you can check than 51 you can't.
More will land as we read more. If your state matters to you and isn't here, tell us — it moves up the list.